From L-R: EPFL professor Christian Heinis, Novo Holdings principal João Ribas and partner Morten Døssing
February 29, 2024 06:30 AM EST
Financing
Startups

No­vo Hold­ings in­vests in macro­cy­cle start­up Or­bis as once-over­looked mol­e­cules get new in­ter­est

Lei Lei Wu

News Reporter

At long last, macro­cy­cles are spin­ning in­to the spot­light.

On Thurs­day, Or­bis Med­i­cines launched with €26 mil­lion in seed fund­ing from Eu­ro­pean VC fund For­bion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times